A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of Tanezumab On Peripheral Nerve Function In Patients With Osteoarthritis.

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Multicenter Study Of Tanezumab On Peripheral Nerve Function In Patients With Osteoarthritis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2014

At a glance

  • Drugs Tanezumab (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Sep 2012 Results presented at the 16th Congress of the European Federation of Neurological Societies.
    • 16 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 16 Dec 2010 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top